LONG-TERM SAFETY AND EFFICACY OF CANAKINUMAB VS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH FREQUENT ACUTE GOUTY ARTHRITIS ATTACKS WHO ARE CONTRAINDICATED, INTOLERANT OR UNRESPONSIVE TO NSAIDS AND/OR COLCHICINE

被引：1

作者：

Alten, R.

Schlesinger, N. ^{[1
]}

So, A. ^{[2
]}

Schumacher, H. R. ^{[3
,4
]}

Bloch, M. T. ^{[5
]}

Machein, U. ^{[6
]}

Richard, D. ^{[6
]}

Lheritier, K. ^{[6
]}

Bardin, T. ^{[7
]}

机构：

[1] Rutgers RWJMS, New Brunswick, NJ USA

[2] CHU Vaudois, Serv Rhumatol, Lausanne, Switzerland

[3] Univ Penn, Philadelphia, PA 19104 USA

[4] VA Med Ctr, Philadelphia, PA USA

[5] Holdsworth House Med Practice, Sydney, NSW, Australia

[6] Novartis Pharma AG, Basel, Switzerland

[7] Hop Lariboisiere, F-75475 Paris, France

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷

关键词：

D O I：

10.1136/annrheumdis-2014-eular.1807

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0537

引用

页码：785 / 785

页数：1

共 41 条

[21] Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Followup Study
Brunner, Hermine L.
Ruperto, Nicolino
Quartier, Pierre
Constantin, Tamas
Alexeeva, Ekaterina
Schneider, Rayfel
Kone-Paut, Isabelle
Schikler, Kenneth
Marzan, Katherine
Wulffraat, Nico
Padeh, Shai
Chasnyk, Vyacheslav
Wouters, Carine
Kuemmerle-Deschner, Jasmin B.
Kallinich, Tilmann
Lauwerys, Bernard
Haddad, Elie
Nasonov, Evgeny L.
Trachana, Maria
Vougiouka, Olga
Leon, Karolynn
Speziale, Antonio
Lheritier, Karine
Vritzali, Eleni
Lovell, Daniel J.
Martini, Alberto
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[22] LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM THE RANDOMISED PHASE 3 CLUSTER TRIAL
Ozen, S.
Ben-Chetrit, E.
Foeldvari, I.
Amarilyo, G.
Ozdogan, H.
Vanderschueren, S.
Marzan, K.
Kahlenberg, J. M.
Dekker, E.
De Benedetti, F.
Kone-Paut, I.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 169 - 170
[23] Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
Ozen, Seza
Ben-Cherit, Eldad
Foeldvari, Ivan
Amarilyo, Gil
Ozdogan, Huri
Vanderschueren, Steven
Marzan, Katherine
Kahlenberg, J. Michelle
Dekker, Elise
De Benedetti, Fabrizio
Kone-Paut, Isabelle
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1362 - 1369
[24] Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'
Satis, Hasan
Aydemir, Ergin
Izmirlioglu, Kerem
Tufan, Abdurrahman
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12) : e256
[25] Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
Brunner, Hermine I.
Ruperto, Nicolino
Quartier, Pierre
Constantin', Tamas
Alexeeva, Ekaterina
Kone-Paut, Isabelle
Marzan, Katherine
Wulffraat, Nico
Schneider, Rayfel
Padeh, Shai
Chasnyk, Vyacheslav
Wouters, Carine
Kuemmerle-Deschner, Jasmin B.
Kallinich, Tilmann
Lauwerys, Bernard
Haddad, Elie
Nasonov, Evgeny L.
Trachana, Maria
Vougiouka, Olga
Leon, Karolynn
Vritzali, Eleni
Lheritier, Karine
Martinis, Alberto
Lovell, Daniel J.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[26] Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders
Amano, Koichi
Matsubara, Tsukasa
Tanaka, Takaaki
Inoue, Hiroshi
Iwahashi, Mitsuhiro
Kanamono, Toshihisa
Nakano, Teruaki
Uchimura, Shoichi
Izumihara, Tomomaro
Yamazaki, Akira
Karyekar, Chetan S.
Takeuchi, Tsutomu
MODERN RHEUMATOLOGY, 2015, 25 (05) : 665 - 671
[27] Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
De Benedetti, Fabrizio
Frenkel, Joost
Simon, Anna
Anton, Jordi
Lachmann, Helen J.
Gattorno, Marco
Ozen, Seza
Kone-Paut, Isabelle
Ben-Chetrit, Eldad
Wozniak, Magdalena
Wei, Xiaoling
Vritzali, Eleni
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[28] LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FMF (CRFMF), TRAPS AND HIDS/MKD: RESULTS FROM THE PIVOTAL PHASE 3 CLUSTER TRIAL
De Benedetti, F.
Frenkel, J.
Simon, A.
Anton, J.
Lachmann, H.
Gattorno, M.
Ozen, S.
Kone-Paut, I.
Ben-Chetrit, E.
Wozniak, M. B.
Wang, J. G.
Vritzali, E.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 486 - 487
[29] Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Brunner, Hermine
Ruperto, Nicolino
Quartier, Pierre
Constantin, Tamas
Alexeeva, Ekaterina
Schneider, Rayfel
Kone-Paut, Isabelle
Schikler, Kenneth N.
Marzan, Katherine
Wulffraat, Nico
Padeh, Shai
Chasnyk, Vyacheslav
Wouters, Carine
Kuemmerle-Deschner, Jasmin B.
Kallinich, Tilmann
Lauwerys, Bernard
Haddad, Elie
Nasonov, Evgeny L.
Trachana, Maria
Vougiouka, Olga
Leon, Karolynn
Speziale, Antonio
Lheritier, Karine
Vritzali, Eleni
Martini, Alberto
Lovell, Daniel
ARTHRITIS & RHEUMATOLOGY, 2017, 69 : 7 - 8
[30] Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study
Iwata, Naomi
Nishimura, Kenichi
Hara, Ryoki
Imagawa, Tomoyuki
Shimizu, Masaki
Tomiita, Minako
Umebayashi, Hiroaki
Takei, Syuji
Seko, Noriko
Wakabayashi, Ryota
Yokota, Shumpei
MODERN RHEUMATOLOGY, 2023, 33 (06) : 1162 - 1170

← 1 2 3 4 5 →